

SUMITOMO CHEMICAL COMPANY, LIMITED

Notice of the 139th Ordinary General Meeting of Shareholders

THIS DOCUMENT IS A SUMMARY OF A NOTICE AND THE ATTACHMENTS THERETO, THE ORIGINALS OF WHICH ARE IN THE JAPANESE LANGUAGE. THIS DOCUMENT IS MADE ONLY FOR THE REFERENCE PURPOSES OF SHAREHOLDERS WHO LIVE IN COUNTRIES OUTSIDE OF JAPAN AND DOES NOT CONSTITUTE A FORMAL TRANSLATION OF THE ORIGINAL NOTICE AND THE ATTACHMENTS. IN THIS SUMMARY, CERTAIN INFORMATION IS INTENTIONALLY OMITTED. THE ORIGINALS CONTAIN MORE INFORMATION, SUCH AS THE REPORTS OF THE ACCOUNTING AUDITORS AND THE BOARD OF CORPORATE AUDITORS, ETC., WHILE SOME SUPPLEMENTAL INFORMATION NOT CONTAINED IN THE ORIGINALS IS ADDITIONALLY GIVEN IN THIS SUMMARY AS FOOTNOTES WITH ASTERISKS.

To Our Shareholders:

Please take notice that Sumitomo Chemical Company, Limited (the “Company”) has called an Ordinary General Meeting of Shareholders to be held in Tokyo, Japan on June 24, 2020 (the “Meeting”) for the following purposes:

MATTERS TO BE REPORTED:

- No. 1. Reports on the Company’s business report, consolidated financial statements, and the results of both the Accounting Auditor’s and the Board of Corporate Auditors’ audits of the Company’s consolidated financial statements for the 139th fiscal period (from April 1, 2019, to March 31, 2020) (the “139th fiscal period”).
- No. 2. Reports on the Company’s non-consolidated financial statements for the 139th fiscal period.

MATTERS TO BE RESOLVED:

- No. 1. To elect thirteen Directors.

EXPLANATION OF THE SUBJECT MATTERS OF THE MEETING

- No. 1. Reports on the Company's business report, consolidated financial statements, and the results of both the Accounting Auditor's and the Board of Corporate Auditors' audits of the Company's consolidated financial statements for the 139th fiscal period.
- No. 2. Reports on the Company's non-consolidated financial statements for the 139th fiscal period.

* The financial statements for the 139th fiscal period have been audited by the Accounting Auditors (certified public accountants under Japanese law) and the Corporate Auditors of the Company pursuant to the Companies Act (*kaishahou*) (Law No. 86 of 2005).

No. 1. To elect thirteen Directors.

The term of office of all thirteen Directors will expire at the close of this Meeting. Accordingly, the election of thirteen Directors including four Outside Directors is proposed.



The candidates for Directors are as follows:


Candidate No.	Name	Current Principal Occupation and Responsibility at the Company	Attendance at the Board of Directors meetings
1	Masakazu Tokura (Reappointment)	Representative Director, Chairman	13 out of 13 meetings (100%)
2	Keiichi Iwata (Reappointment)	Representative Director, President & Executive President	13 out of 13 meetings (100%)
3	Noriaki Takeshita (Reappointment)	Representative Director & Senior Managing Executive Officer Supervision of Petrochemicals & Plastics Sector	13 out of 13 meetings (100%)
4	Masaki Matsui (Reappointment)	Representative Director & Managing Executive Officer Supervision of IT-related Chemicals Sector, PLED Business Planning, Electronic Devices Development Center	10 out of 10 meetings (100%)
5	Kingo Akahori (Reappointment)	Representative Director & Managing Executive Officer Supervision of Energy & Functional Materials Sector	9 out of 10 meetings (90%)
6	Hiroshi Ueda (Reappointment)	Director & Executive Vice President Supervision of Research Planning and Coordination, Digital and Data Science Innovation, Process & Production Technology & Safety Planning, Production & Safety Fundamental Technology Center, Intellectual Property, Responsible Care, Industrial Technology & Research Laboratory, Environmental Health Science Laboratory, Advanced Materials Development Laboratory, Bioscience Research Laboratory	13 out of 13 meetings (100%)
7	Hiroshi Niinuma (Reappointment)	Director & Senior Managing Executive Officer Supervision of General Affairs, Legal, Sustainability, Internal Control and Audit, Human Resources, Osaka Office Administration, Corporate Communications, Procurement, Logistics	13 out of 13 meetings (100%)


Candidate No.	Name	Current Principal Occupation and Responsibility at the Company	Attendance at the Board of Directors meetings
8	Takashi Shigemori (Reappointment)	Director & Senior Managing Executive Officer Supervision of Corporate Planning, IT Innovation	10 out of 10 meetings (100%)
9	Nobuaki Mito (New appointment)	Managing Executive Officer Supervision of Health & Crop Sciences Sector	—
10	Koichi Ikeda (Reappointment, Outside Director, Independent Officer)	Director	13 out of 13 meetings (100%)
11	Hiroshi Tomono (Reappointment, Outside Director, Independent Officer)	Director	13 out of 13 meetings (100%)
12	Motoshige Itoh (Reappointment, Outside Director, Independent Officer)	Director	12 out of 13 meetings (92%)
13	Atsuko Muraki (Reappointment, Outside Director, Independent Officer)	Director	12 out of 13 meetings (92%)


Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">1</p>  <p>Masakazu Tokura (Reappointment)</p>	<p>April 1974 Joined the Company June 2003 Executive Officer June 2006 Managing Executive Officer June 2008 Representative Director & Managing Executive Officer April 2009 Representative Director & Senior Managing Executive Officer April 2011 Representative Director, President & Executive President April 2014 Representative Director, President & Executive President, COO April 2015 Representative Director, President & Executive President April 2019 Representative Director, Chairman up to the present date</p> <p>[Reason for selection as a Director nominee, etc.] Masakazu Tokura assumed office as an Executive Officer of the Company in 2003. He previously served as a Director & Senior Managing Executive Officer, and has been serving as a Director & Executive President since 2011. He has formulated Corporate Business Plans three times, including the current Corporate Business Plan (from April 2019 to March 2022) and has been focusing on the operations of the Board of Directors of the Company as a Director, Chairman since April 2019. He was continuously selected as a Director nominee since he has extensive business experience and advanced knowledge of the overall business of the Company, as described above.</p>	<p>July 10, 1950</p> <p>243,600 Shares</p>
<p style="text-align: center;">2</p>  <p>Keiichi Iwata (Reappointment)</p>	<p>April 1982 Joined the Company April 2010 Executive Officer April 2013 Managing Executive Officer April 2018 Senior Managing Executive Officer June 2018 Representative Director & Senior Managing Executive Officer April 2019 Representative Director, President & Executive President up to the present date</p> <p>[Reason for selection as a Director nominee, etc.] Keiichi Iwata assumed office as an Executive Officer of the Company in 2010. He previously served as a Director & Senior Managing Executive Officer, and has worked to promote the current Corporate Business Plan (from April 2019 to March 2022) as a Director & Executive President since April 2019. He was continuously selected as a Director nominee since he has extensive business experience and advanced knowledge of the overall business of the Company, as described above.</p>	<p>October 11, 1957</p> <p>112,100 Shares</p>


Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">3</p>  <p>Noriaki Takeshita (Reappointment)</p>	<p>April 1982 Joined the Company April 2010 Executive Officer April 2013 Managing Executive Officer June 2017 Representative Director & Managing Executive Officer April 2018 Representative Director & Senior Managing Executive Officer up to the present date</p> <p>Current Responsibility at the Company Supervision of Petrochemicals & Plastics Sector</p> <p>Important Concurrent Post Deputy Chairman of Rabigh Refining and Petrochemical Company</p> <p>[Reason for selection as a Director nominee, etc.] Noriaki Takeshita assumed office as an Executive Officer of the Company in 2010. He previously served as a Managing Executive Officer and Director & Managing Executive Officer, and has been serving as a Director & Senior Managing Executive Officer since 2018. He has been in charge of the Rabigh Project and the Petrochemicals & Plastics Sector, and has utilized his knowledge and experience for the benefit of the overall business of the Company as a Director. He was continuously selected as a Director nominee since he has extensive business experience and advanced knowledge of the overall business of the Company, as described above.</p>	<p>July 23, 1958</p> <p>65,800 Shares</p>


Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">4</p>  <p style="text-align: center;">Masaki Matsui (Reappointment)</p>	<p>April 1985 Joined the Company April 2013 Executive Officer April 2017 Managing Executive Officer June 2019 Representative Director & Managing Executive Officer up to the present date</p> <p>Current Responsibility at the Company Supervision of IT-related Chemicals Sector, PLED Business Planning, Electronic Devices Development Center</p> <p>[Reason for selection as a Director nominee, etc.] Masaki Matsui assumed office as an Executive Officer of the Company in 2013. He previously served as a Managing Executive Officer, and has been serving as a Director & Managing Executive Officer since 2019. He has been in charge of the IT-related Chemicals Sector, PLED Business Planning, and Electronic Devices Development Center, and has utilized his knowledge and experience for the benefit of the overall business of the Company as a Director. He was continuously selected as a Director nominee since he has extensive business experience and advanced knowledge of the overall business of the Company, as described above.</p>	<p style="text-align: center;">August 3, 1960</p> <p style="text-align: center;">38,521 Shares</p>
<p style="text-align: center;">5</p>  <p style="text-align: center;">Kingo Akahori (Reappointment)</p>	<p>April 1983 Joined the Company April 2015 Associate Officer April 2016 Executive Officer April 2018 Managing Executive Officer June 2019 Representative Director & Managing Executive Officer up to the present date</p> <p>Current Responsibility at the Company Supervision of Energy & Functional Materials Sector</p> <p>[Reason for selection as a Director nominee, etc.] Kingo Akahori assumed office as an Executive Officer of the Company in 2016. He previously served as a Managing Executive Officer, and has been serving as a Director & Managing Executive Officer since 2019. He has been in charge of the Energy & Functional Materials Sector, and has utilized his knowledge and experience for the benefit of the overall business of the Company as a Director. He was continuously selected as a Director nominee since he has extensive business experience and advanced knowledge of the overall business of the Company, as described above.</p>	<p style="text-align: center;">August 2, 1957</p> <p style="text-align: center;">32,500 Shares</p>

Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">6</p>  <p style="text-align: center;">Hiroshi Ueda (Reappointment)</p>	<p>April 1982 Joined the Company April 2009 Executive Officer April 2011 Managing Executive Officer April 2016 Senior Managing Executive Officer June 2016 Representative Director & Senior Managing Executive Officer June 2018 Director & Senior Managing Executive Officer April 2019 Director & Executive Vice President up to the present date</p> <p>Current Responsibility at the Company Supervision of Research Planning and Coordination, Digital and Data Science Innovation, Process & Production Technology & Safety Planning, Production & Safety Fundamental Technology Center, Intellectual Property, Responsible Care, Industrial Technology & Research Laboratory, Environmental Health Science Laboratory, Advanced Materials Development Laboratory, Bioscience Research Laboratory</p> <p>[Reason for selection as a Director nominee, etc.] Hiroshi Ueda assumed office as an Executive Officer of the Company in 2009. He previously served as a Managing Executive Officer and Director & Senior Managing Executive Officer, and has been serving as a Director & Executive Vice President since 2019. He has been in charge of the Research Planning and Coordination, Digital and Data Science Innovation, Process & Production Technology & Safety Planning, Production & Safety Fundamental Technology Center, Intellectual Property, Responsible Care, Industrial Technology & Research Laboratory, Environmental Health Science Laboratory, Advanced Materials Development Laboratory, and Bioscience Research Laboratory, and has utilized his knowledge and experience for the benefit of the overall business of the Company as a Director. He was continuously selected as a Director nominee since he has extensive business experience and advanced knowledge of the overall business of the Company, as described above.</p>	<p>August 5, 1956</p> <p>100,900 Shares</p>


Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">7</p>  <p>Hiroshi Niinuma (Reappointment)</p>	<p>April 1981 Joined the Company April 2010 Executive Officer April 2013 Managing Executive Officer April 2018 Senior Managing Executive Officer June 2018 Director & Senior Managing Executive Officer up to the present date</p> <p>Current Responsibility at the Company Supervision of General Affairs, Legal, Sustainability, Internal Control and Audit, Human Resources, Osaka Office Administration, Corporate Communications, Procurement, Logistics</p> <p>Important Concurrent Post Outside Director of Sumitomo Seika Chemicals Co., Ltd.</p> <p>[Reason for selection as a Director nominee, etc.] Hiroshi Niinuma assumed office as an Executive Officer of the Company in 2010. He previously served as a Managing Executive Officer, and has been serving as a Director & Senior Managing Executive Officer since 2018. He has been in charge of General Affairs, Legal, CSR, Internal Control and Audit, Human Resources, Osaka Office Administration, Corporate Communications, Procurement and Logistics, and has utilized his knowledge and experience for the benefit of the overall business of the Company as a Director. He was continuously selected as a Director nominee since he has extensive business experience and advanced knowledge of the overall business of the Company, as described above.</p>	<p>March 5, 1958</p> <p>78,600 Shares</p>


Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">8</p>  <p>Takashi Shigemori (Reappointment)</p>	<p>April 1983 Joined the Company April 2012 Executive Officer April 2016 Managing Executive Officer April 2019 Senior Managing Executive Officer June 2019 Director & Senior Managing Executive Officer up to the present date</p> <p>Current Responsibility at the Company Supervision of Corporate Planning, IT Innovation</p> <p>Important Concurrent Post Director of Rabigh Refining and Petrochemical Company President of Japan-Singapore Petrochemicals Co., Ltd.</p> <p>[Reason for selection as a Director nominee, etc.] Takashi Shigemori assumed office as an Executive Officer of the Company in 2012. He previously served as a Managing Executive Officer, and has been serving as a Director & Senior Managing Executive Officer since 2019. He has been in charge of Corporate Business Development, Corporate Planning, IT Innovation, Accounting, and Finance, and has utilized his knowledge and experience for the benefit of the overall business of the Company as a Director. He was continuously selected as a Director nominee since he has extensive business experience and advanced knowledge of the overall business of the Company, as described above.</p>	<p>October 3, 1958</p> <p>33,930 Shares</p>

Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">9</p>  <p style="text-align: center;">Nobuaki Mito (New appointment)</p>	<p>April 1985 Joined the Company April 2014 Associate Officer April 2015 Executive Officer April 2018 Managing Executive Officer up to the present date</p> <p>Current Responsibility at the Company Supervision of Health & Crop Sciences Sector</p> <p>Important Concurrent Post Chairman of Valent U.S.A. LLC Chairman of Valent BioSciences LLC</p> <p>[Reason for selection as a Director nominee, etc.] Since joining the Company, Nobuaki Mito has mainly engaged in research and development in the Health & Crop Sciences Sector, and has experienced formulation and promotion of the policies for technology, research and development in the Planning & Coordination Office in the sector. After being appointed as an Executive Officer in 2015, he has been in charge of the Corporate Business Development Dept. and Intellectual Property Dept., and engaged in development of next-generation businesses and formulation and promotion of the strategy for intellectual property. He also has promoted the current Corporate Business Plan (from April 2019 to March 2022) in the sector as an officer in charge of offices and divisions in the Health & Crop Sciences Sector since April 2019. He was selected as a Director nominee since he has extensive business experience and advanced knowledge of the overall business of the Company, as described above.</p>	<p style="text-align: center;">August 4, 1960</p> <p style="text-align: center;">30,200 Shares</p>

Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">10</p>  <p style="text-align: center;">Koichi Ikeda (Reappointment, Outside Director, Independent Officer)</p>	<p>April 1963 Joined Asahi Breweries, Ltd. (Currently Asahi Group Holdings, Ltd.)</p> <p>March 1992 Commissioner of Asahi Breweries, Ltd.</p> <p>March 1996 Director of Asahi Breweries, Ltd.</p> <p>March 1997 Managing Director of Asahi Breweries, Ltd.</p> <p>March 1999 Senior Managing Director of Asahi Breweries, Ltd.</p> <p>March 2000 Senior Managing Executive Officer of Asahi Breweries, Ltd.</p> <p>March 2001 Senior Managing Director & Senior Managing Executive Officer of Asahi Breweries, Ltd.</p> <p>January 2002 Representative Director & President & COO of Asahi Breweries, Ltd.</p> <p>March 2006 Representative Director & Chairman & CEO of Asahi Breweries, Ltd.</p> <p>March 2010 Adviser of Asahi Breweries, Ltd.</p> <p>June 2011 Outside Corporate Auditor of the Company</p> <p>July 2011 Adviser of Asahi Group Holdings, Ltd.</p> <p>up to the present date</p> <p>June 2015 Outside Director of the Company</p> <p>up to the present date</p> <p>[Reason for selection as an Outside Director nominee, etc.] Koichi Ikeda was continuously selected as an Outside Director nominee to supervise the management of the Company by making use of his abundant experience and extensive knowledge as a management executive of a business corporation.</p>	<p>April 21, 1940</p> <p>0 Shares</p>

Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">11</p>  <p>Hiroshi Tomono (Reappointment, Outside Director, Independent Officer)</p>	<p>April 1971 Joined Sumitomo Metal Industries, Ltd. (Currently NIPPON STEEL CORPORATION)</p> <p>June 1998 Director of Sumitomo Metal Industries, Ltd.</p> <p>June 1999 Managing Executive Officer of Sumitomo Metal Industries, Ltd.</p> <p>April 2003 Senior Managing Executive Officer of Sumitomo Metal Industries, Ltd.</p> <p>June 2003 Director & Senior Managing Executive Officer of Sumitomo Metal Industries, Ltd.</p> <p>April 2005 Representative Director & Vice President of Sumitomo Metal Industries, Ltd.</p> <p>June 2005 Representative Director & President of Sumitomo Metal Industries, Ltd.</p> <p>October 2012 Representative Director & President & COO of Nippon Steel & Sumitomo Metal Corporation (Currently NIPPON STEEL CORPORATION)</p> <p>April 2014 Representative Director & Vice Chairman of Nippon Steel & Sumitomo Metal Corporation</p> <p>April 2015 Director & Adviser of Nippon Steel & Sumitomo Metal Corporation</p> <p>June 2015 Adviser of Nippon Steel & Sumitomo Metal Corporation</p> <p>up to the present date</p> <p>June 2015 Outside Director of the Company</p> <p>up to the present date</p> <p>Important Concurrent Post</p> <p style="padding-left: 40px;">Outside Director of Japan Nuclear Fuel Limited</p> <p>[Reason for selection as an Outside Director nominee, etc.] Hiroshi Tomono was continuously selected as an Outside Director nominee to supervise the management of the Company by making use of his abundant experience and extensive knowledge as a management executive of a business corporation.</p>	<p>July 13, 1945</p> <p style="text-align: center;">0 Shares</p>

Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">12</p>  <p style="text-align: center;">Motoshige Itoh (Reappointment, Outside Director, Independent Officer)</p>	<p>December 1993 Professor, Faculty of Economics, The University of Tokyo</p> <p>April 1996 Professor, Graduate School of Economics, The University of Tokyo</p> <p>October 2007 Dean, Graduate School of Economics, Faculty of Economics, The University of Tokyo</p> <p>April 2016 Professor, Faculty of International Social Sciences, Gakushuin University</p> <p>up to the present date</p> <p>June 2018 Outside Director of the Company up to the present date</p> <p>Important Concurrent Post</p> <ul style="list-style-type: none"> Outside Director of East Japan Railway Company Outside Director of THE SHIZUOKA BANK, LTD. Outside Corporate Auditor of Hagoromo Foods Corporation <p>[Reason for selection as an Outside Director nominee, etc.] Motoshige Itoh was continuously selected as an Outside Director nominee to supervise the management of the Company by making use of his expert knowledge of economics, etc. through his long experience as a university professor; and of his wealth of experience and extensive knowledge of economic, social and other issues from his track record as a member of various government deliberative committees. Although Motoshige Itoh only has experience with enterprise management as an outside director or auditor, the Company has determined that he is capable of appropriately performing the duties of an Outside Director of the Company, due to the reasons mentioned above.</p>	<p>December 19, 1951</p> <p>0 Shares</p>

Candidate No. Name	Career Summary, Principal Occupation and Responsibility at the Company, and Important Concurrent Post	Birth Date The Number of Shares Owned in the Company
<p style="text-align: center;">13</p>  <p style="text-align: center;">Atsuko Muraki (Reappointment, Outside Director, Independent Officer)</p>	<p>April 1978 Joined Ministry of Labour (Currently Ministry of Health Labour and Welfare)</p> <p>October 2005 Counsellor for Policy Evaluation, Minister's Secretariat of Ministry of Health Labour and Welfare</p> <p>September 2006 Deputy Director-General, Equal Employment, Children and Families Bureau of Ministry of Health Labour and Welfare</p> <p>July 2008 Director-General, Equal Employment, Children and Families Bureau of Ministry of Health Labour and Welfare</p> <p>September 2010 Director-General for Policies on Cohesive Society of Cabinet Office</p> <p>September 2012 Director-General, Social Welfare and War Victims' Relief Bureau of Ministry of Health Labour and Welfare</p> <p>July 2013 Vice Minister of Health Labour and Welfare of Ministry of Health Labour and Welfare</p> <p>October 2015 Retired from Ministry of Health Labour and Welfare</p> <p>June 2018 Outside Director of the Company up to the present date</p> <p>Important Concurrent Post Outside Member of the Board of ITOCHU Corporation Outside Director of Sompo Holdings, Inc.</p> <p>[Reason for selection as an Outside Director nominee, etc.] Atsuko Muraki was continuously selected as an Outside Director nominee to supervise the management of the Company by making use of her wealth of experience and extensive knowledge in legal, social and other issues deriving from her employment over many years at administrative bodies as a civil servant. Although Atsuko Muraki only has experience with enterprise management as an outside director or auditor, the Company has determined that she is capable of appropriately performing the duties of an Outside Director of the Company, due to the reasons mentioned above.</p>	<p>December 28, 1955</p> <p>0 Shares</p>

- NOTES: 1 None of the above candidates has any conflicts of interest with the Company.
- 2 Mr. Koichi Ikeda, Mr. Hiroshi Tomono, Mr. Motoshige Itoh, and Ms. Atsuko Muraki are the candidates for Outside Directors.
- 3 Mr. Koichi Ikeda, Mr. Hiroshi Tomono, Mr. Motoshige Itoh, and Ms. Atsuko Muraki are currently Outside Directors of the Company. Mr. Koichi Ikeda's term of office will be five years, Mr. Hiroshi Tomono's term of office will be five years, Mr. Motoshige Itoh's term of office will be two years, and Ms. Atsuko Muraki's term of office will be two years at the close of this Meeting. Mr. Koichi Ikeda assumed office as an Outside Corporate Auditor of the Company on June 23, 2011,

and retired on June 23, 2015.

4 Pursuant to the regulations of the Tokyo Stock Exchange, Inc., the Company has designated Mr. Koichi Ikeda, Mr. Hiroshi Tomono, Mr. Motoshige Itoh, and Ms. Atsuko Muraki as Independent Directors who have no risk of having conflicts of interest with ordinary shareholders.

5 In December 2016, Japan Nuclear Fuel Limited, where Mr. Hiroshi Tomono has served as an Outside Director since June 2016, received an order to submit a report (“Collection of Reports”) from the Nuclear Regulation Authority regarding safety violations. He was not aware of each matter related to the receipt of such an order in advance, but had always expressed his opinions from the perspective of compliance at Board of Directors meetings, etc., and even after receiving the order, fulfilled his responsibility as an Outside Director, such as instructing through inspections and measures to prevent reoccurrence.

6 On January 12, 2018 and July 12, 2018, ITOCHU Corporation, where Ms. Atsuko Muraki has been an Outside Member of the Board since June 2016, was sanctioned by the Japan Fair Trade Commission with a cease and desist order relating to violations of the Antimonopoly Act. In addition, on October 18, 2018, ITOCHU Corporation was sanctioned with a cease and desist order and a surcharge payment order relating to violations of the Antimonopoly Act. Ms. Atsuko Muraki was unaware of circumstances relating to the cease and desist order and the surcharge payment order before the event, but has regularly made comments at the Board of Directors meetings, etc. regarding the importance of compliance with laws and regulations. After said facts were discovered, she has actively provided advice on further compliance with laws and regulations and the formulation of plans to prevent recurrence, and has accordingly fulfilled her duties in such capacity.

7 The Company executed limitation of liability contracts with Mr. Koichi Ikeda, Mr. Hiroshi Tomono, Mr. Motoshige Itoh, and Ms. Atsuko Muraki that limit their liabilities for damages to the Company pursuant to Article 423(1) of the Companies Act, up to the total of the amounts listed in the items of Article 425(1) of the Companies Act (the “Limitation of Liability Contracts”). When they are reappointed to Outside Directors of the Company, the Company will continue the Limitation of Liability Contracts.

(Reference)

Criteria for Designation of Independent Directors & Auditors (Revised June 23, 2015)

1. These criteria set conditions for designation of the Company's Outside Directors & Auditors (meaning Outside Directors and Outside Corporate Auditors) as "Independent Directors & Auditors" defined in the listing rules of stock exchanges in Japan.
2. If none of the conditions given in (1) to (9) below applies, a person, in principle, shall be considered to have no material interest in the Company and may be designated as Independent Directors & Auditors.

The person

- (1) Is an executor of business, i.e. someone who executes business of the Company or a company of the Company's Group (a Director (other than Outside Director), an executive officer, or an employee (by whatever name, someone having an employment relationship with the Company or with the company of the Group)).
- (2) Is an executor of business who executes business of a major client or business partner of the Company. The "a major client or business partner" means any of the following.
 - (a) A vendor providing products or services to the Company, or a customer to which the Company is providing products or services, of which the total amount of such transactions in the fiscal year nearest to the time of intended designation as an Independent Directors & Auditors exceeds 2% of their total sales or exceeds 2% of the Company's nonconsolidated sales, respectively.
 - (b) A financial institution providing loans to the Company, of which the total amount of the loans at the end of the fiscal year nearest to the time of intended designation as Independent Directors & Auditors exceeds 2% of the Company's total nonconsolidated borrowings; provided that, even if the amount does not exceed 2%, a financial institution indicated as a lender to the Company on annual securities reports, business reports or other public documents shall be considered "a major business partner."
- (3) A consultant, certified public accountant, attorney or other expert receiving remuneration from the Company in addition to the remuneration payable to the Company's Directors, Officers, Etc., of which the total amount of the remuneration paid, other than the remuneration payable to the Company's Directors, Officers, Etc., in the fiscal year nearest to the time of intended designation as Independent Directors & Auditors exceeds 10 million yen; provided that, even if the amount does not exceed 10 million yen, the person shall be considered a recipient of a substantial amount of remuneration if it exceeds 50% of that person's annual income.
- (4) A person who works for an organization that is a consulting firm, tax accounting firm, law office, other corporate body, partnership, etc., whose sales to the Company in the fiscal year nearest to the time of intended designation as Independent Directors & Auditors exceeds 2% of the organization's total sales or 10 million yen, whichever is larger.
- (5) A shareholder of the Company whose share of voting rights at the end of the fiscal year nearest to the time of intended designation as Independent Directors & Auditors is 10% or more (a total of direct and indirect holdings) or an executor of business at the shareholder entity.

- (6) Of the companies in which the Company holds shares, an entity in which the Company's share of voting rights at the end of the fiscal year nearest to the time of intended designation as Independent Directors & Auditors is 10% or more (a total of direct and indirect holdings) or an executor of business at the entity.
 - (7) A person who works for an auditing firm that conducts statutory audits of the Company.
 - (8) A person to whom (1) above was applicable in the past or to whom any of (2) to (7) above was applicable in the past one year or equivalent period.
 - (9) A spouse or a close relative (second-degree relative or closer) of a person to whom any of the following applies.
 - (a) A person listed in (1) to (7) above.
 - (b) A person who, in the past year or equivalent period, was an executor of business of the Company or a company of the Company's Group. If an outside Corporate Auditor is to be designated as Independent Directors & Auditors, a Director not executing business or an accounting advisor (including its employees who are to perform relevant specific duties if the accounting advisor is a body corporate).
 - (c) In (a) and (b) above, "an executor of business" shall mean a person executing an important business at a company or a business partner, i.e. a Director having business execution functions, an Executive Officer or an employee having a position of department manager, its equivalent or above, and shall not include persons below the position of department manager or its equivalent.
 - (d) The above (a) notwithstanding, a person who "works for an organization" in (4) above shall not include a person who is neither an executor of important business in the organization nor, if the organization is an auditing firm, law office or other organization specializing in accounting or law, etc., a person who has specialized qualifications, such as a certified public accountant and attorney.
 - (e) The above (a) notwithstanding, a person who "works for an auditing firm" in (7) above shall include neither a person who is not an executor of important business in the firm nor a person who does not have specialized qualifications, such as a certified public accountant.
3. Even where the conditions set forth in 2. above do not apply, if there are circumstances that, in the judgment of the Company, sufficiently indicates any of Outside Directors & Auditors being incapable of performing his or her duties as Independent Directors & Auditors, that particular Outside Directors & Auditors shall not be designated as Independent Directors & Auditors.
 4. With respect to an Outside Directors & Auditors whom the Company intends to designate as Independent Directors & Auditors in accordance with the foregoing, the Company shall, upon his or her written consent, designate that Outside Directors & Auditors as Independent Directors & Auditors, and shall make notification thereof to the stock exchanges on which the Company is listed. Prior to making the notification, the matter shall be reported to the Board of Directors and the Board of Corporate Auditors.

Business Report

(April 1, 2019 - March 31, 2020)

1. Overview of the Company Group

(1) Business Progress and Results

The economic condition outside Japan during the fiscal 2019 has shown clear signs of overall slowdown as evidenced by bleak outlook on the US economy, which has been driving the global economy for some time, and by the changes in Chinese economy impacted by the US-China trade war.

Around the time when the Japanese economy was beginning to be in a lull, the consumption tax hike and damages from frequent heavy rainfall caused sharp decline in consumer spending, resulting in adverse business environment.

Amid these circumstances, the new coronavirus (COVID-19) began to spread, having a severe negative impact on economic activity in China, and then in all over the world.

Against this backdrop, the Sumitomo Chemical Group has formulated its Corporate Business Plan (for fiscal 2019 - fiscal 2021), centering on the basic policies of accelerating the development of next-generation businesses, improving productivity through digital innovation, sophisticating the Company's business portfolio, and building a more robust financial structure. The Group has come together, working to create a sustainable society and to deliver its sustainable growth through exponential growth in productivity and acceleration of innovation.

As a result, the Sumitomo Chemical Group's sales revenue for this fiscal year totaled ¥2,225.8 billion, a decrease of ¥92.8 billion compared with the previous fiscal year. The Group posted core operating income (Note) of ¥132.7 billion, operating income of ¥137.5 billion, and net income attributable to owners of the parent of ¥30.9 billion, all of which fell short of the results for the previous fiscal year. The Company's non-consolidated sales amounted to ¥678.4 billion, and net income was ¥22.8 billion.

Note: "Core operating income" is a gain and loss concept, reflecting recurring earning capacity, and deducts gains and losses incurred by non-recurring factors from operating income. It includes the share of profit of investments accounted for using the equity method.

As mentioned above, the results for this fiscal year were severe, and since the future business environment is in an unpredictable situation, we would like to express our deep regrets to our shareholders that the Company has decided to pay a year-end dividend of ¥6 per share. As a result, the Company's annual dividend for fiscal 2019 is ¥17 per share, including an interim dividend of ¥11 per share.

Financial Results by Business Segment

Petrochemicals & Plastics

Market conditions for petrochemical products and synthetic resins declined because feedstock prices fell year on year. Market prices for raw materials for synthetic fibers and methyl methacrylate (MMA) also hovered around at a low level. As a result, the sales revenue declined by ¥100.6 billion from the previous fiscal year to ¥656.9 billion. Core operating income declined by ¥47.1 billion to ¥14.5 billion, amid the deteriorated margins

of petrochemical products and MMA.

Energy & Functional Materials

Shipments of resorcinol (a raw material for adhesives) stayed firm. Meanwhile, market prices for aluminum and for the metal raw materials for positive electrode materials remained low, resulting in lower selling prices. The sales revenue declined by ¥27.8 billion from the previous fiscal year to ¥255.0 billion, and core operating income declined by ¥2.6 billion year on year to ¥20.3 billion.

IT-related Chemicals

Despite the drop in selling prices of polarizing film, shipments of polarizing film for both TV and mobile applications, as well as touchscreen panels increased, due to growth in demand. As a result, the sales revenue increased by ¥8.0 billion from the previous fiscal year to ¥404.9 billion. Core operating income fell by ¥1.1 billion year on year to ¥25.1 billion as it is largely impacted by lower selling prices.

Health & Crop Sciences

While market prices for methionine (feed additive) declined, shipments increased because of the increased production capacity in the previous fiscal year. On the other hand, shipments of crop protection products decreased due to the extreme weather in North America. As a result, the sales revenue increased by ¥5.6 billion from the previous fiscal year to ¥343.7 billion. Core operating income declined by ¥17.6 billion year on year to ¥2.1 billion, due to the deteriorated margins of methionine and lower shipments of crop protection products.

Pharmaceuticals

In Japan, sales increased, due to factors including the sales launch of Equa® and EquMet® (for type II diabetes mellitus). In North America, sales of Latuda® (atypical antipsychotic) increased. As a result, the sales revenue increased by ¥23.7 billion from the previous fiscal year to ¥515.8 billion. While sales revenue increased, sales expenses, general and administrative expenses (SG&A), and research and development expenses also increased. This was because the expenses at Sumitovant Biopharma and its subsidiaries (which were acquired as part of the strategic alliance with Roivant Sciences Ltd.) were recognized. Core operating income thus fell by ¥5.5 billion to ¥75.3 billion.

Others

In addition to the above five segments, the Sumitomo Chemical Group supplies electric power and steam, designs chemical plants/supervises the construction of those facilities, provides transportation and warehousing, and conducts physical property analysis/environmental analysis. The sales revenue of these businesses declined by ¥1.7 billion from the previous fiscal year to ¥49.5 billion, and core operating income decreased by ¥0.7 billion to ¥8.8 billion.

Capital Expenditures

In the fiscal year under review, the Companies' capital expenditures totaled ¥116.3 billion, which includes investments for new installations and the expansion of manufacturing facilities as well as renovations and rationalization of existing facilities.

Major facilities completed in the fiscal year under review includes the expansion of the manufacturing facility for processing chemicals for semiconductors in China in the IT-related Chemicals Sector.

Major facilities under construction in the fiscal year under review includes the expansion of the Company's Photoresist Quality Assurance System maintenance in the IT-related Chemicals Sector and the expansion of a domestic subsidiary's positive electrode materials manufacturing facilities in the Energy & Functional Materials Sector. In addition, in the fiscal year under review, investments were made to introduce the Company's next-

generation core business system “SAP S/4 HANA.”

Financing

To respond to financing needs during the fiscal year under review, the Company raised funds, primarily via borrowings from banks and the issue of corporate bonds. Additionally, the Company issued unsecured subordinated bonds with interest payment deferrable clause and optional early redemption conditions in the amount of ¥250 billion in December 2019.

As a result, the balance of borrowings (including corporate bonds) increased by ¥465.1 billion from the previous fiscal year, to ¥1,304.7 billion.

Significant Corporate Restructuring, Etc.

A consolidated subsidiary of the Company, Sumitomo Dainippon Pharma Co., Ltd. acquired all shares of Sumitovant Biopharama Ltd., a new company that was formed under a strategic alliance with Roivant Sciences Ltd. on December 27, 2019. As a result, Sumitovant Biopharama Ltd. and all of its subsidiaries became the consolidated subsidiaries of Sumitomo Dainippon Pharma Co., Ltd.

(2) Issues to be Addressed

Sumitomo Chemical's Vision

With our origins in overcoming the environmental issue of smoke pollution at the Besshi copper mine and increasing crop yields, we have unceasingly pioneered new technology and transformed our businesses while supporting abundant lifestyles for people through our businesses for over 100 years since our founding.

Sumitomo has a traditional concept: "Harmony between the individual, the nation and society" (Sumitomo manifests this concept by seeking to benefit not only its own business, but also both the nation and society). It can be said that the Company's history shows that it has embodied this business spirit and created both economic value and social value in an integrated manner for over 100 years.

Going forward, by contributing to reducing environmental impact and resolving social issues such as food shortage problems, healthcare, and technological innovation in Information and Communication Technology (ICT) through our businesses, we will aim to achieve sustained growth of the Group and realize a sustainable society.

Corporate Business Plan from FY2019 to FY2021

The Group is working on a Corporate Business Plan with FY2019 as the first fiscal year. This plan is the third stage of the "Change & Innovation" project which we have been working on since FY2013. Under the slogan "Change and Innovation 3.0 for a Sustainable Future," we will accelerate innovation while promoting digital innovation to significantly improve productivity.

The basic policies are as follows:

1) Accelerating the development of next-generation businesses

We have identified Health Care, Reducing Environmental Impact, Food, and ICT as the four priority areas. We will collaborate with academia and startups to develop next-generation technologies and create new businesses for building a sustainable society.

2) Improve productivity through digital innovation

By the expanded use of digital technologies (AI and IoT), we will realize drastic improvement in productivity in R&D, manufacturing, supply chain, sales, and indirect departments.

3) Further improve business portfolio

We will further improve our business portfolio by concentrating management resources on those businesses where we can expect sustainable market growth and technology can play a key role as a source of competitiveness.

4) Build a more robust financial structure

We will build a more robust financial structure by controlling costs and assets through more effectively managed operations.

In addition to the four points above, the Company will also work to: 5) Employ, develop and leverage human resources for sustainable growth; and 6) Ensure full and strict compliance and maintain safe and stable operations.

Large-scale strategic investment in FY2019

Under the Corporate Business Plan, the Group determined the following large-scale strategic investments in FY2019 for sustainable growth in the future.

1) Acquisition of the South American businesses of Australian agricultural chemical company Nufarm Ltd.

In September 2019, the Company determined to acquire four South American subsidiaries from Australia's leading agricultural chemical company Nufarm Ltd. for A\$1,188 million, and completed the procedure in April 2020.

This acquisition taking over the bases in South America, including Brazil, which is the world's largest agricultural chemical market, will dramatically advance the development of a series of global footprints (our own sales network) promoted by the Company.

In addition, from 2021 onward the Group plans to launch a new large-scale fungicide product in South America that has a large product market, and the acquisition is expected to significantly contribute to the maximization of sales of the product at an early stage.

With the dramatic expansion of the South American business as a main growth driver, we are aiming to raise the sales revenue of our agricultural chemical business from about 300.0 billion yen to about 550.0 billion yen by FY2025.

2) Strategic alliance with Roivant Sciences Ltd.

In December 2019, Sumitomo Dainippon Pharma Co., Ltd., a consolidated subsidiary of the Company, completed procedures related to a strategic alliance with Roivant Sciences, Ltd. ("Roivant"), which has its head office in Europe. As compensation for the strategic alliance, Sumitomo Dainippon Pharma Co., Ltd. paid a total of approximately US\$3.0 billion to Roivant.

As a result, we acquired multiple new drug candidates, including blockbuster candidates, which will be a growth engine after the end of the exclusive sales period of Latuda® (atypical antipsychotic), which is leading the business performance of the Pharmaceuticals Sector in the Group.

Additionally, the acquisition of an innovative healthcare technology platform developed by Roivant and its competent human resources involved will significantly improve R&D productivity, and accelerate digital innovation.

For the time being, the burden of sales expenses and R&D expenses will increase, but we expect to see a dramatic growth in around 2024 to 2025 as sales of the newly procured drug grow.

Progress of the Corporate Business Plan in FY2019

Major progress at each business sector are as follows:

Petrochemicals & Plastics

Commercial operations of the Rabigh Phase II Project started in November 2019. By expanding the complex, we will supply a wider range of petrochemical products. We have also increased our catalyst production capacity in Japan, and we will earn stable profits through catalyst sales and licensing business.

Energy & Functional Materials

Tanaka Chemical Corporation, a consolidated subsidiary of the Company, signed a manufacturing technology support and sales contract with a European battery manufacturer for a positive electrode material precursor. In the future, we will aim for further expansion of the positive electrode material business for lithium-ion secondary batteries which are mainly used in automotive applications.

IT-related Chemicals

In the semiconductor materials business, a new factory for photoresists has been constructed and is scheduled to start operations in FY2020.

We are also working to add value in the optically functional film business, such as by making Sanritz Corporation a subsidiary to make a full-scale entry into the automotive field.

Health & Crop Sciences

In addition to the previously mentioned acquisition of the South American business of Nufarm Ltd., we have completed the integration of two subsidiaries in India, the world's fifth largest agricultural chemicals market. Regarding methionine (feed additive), we have proceeded with efforts to optimize production systems, including suspension of old plants with low production efficiency.

Pharmaceuticals

In addition to the previously mentioned strategic alliance with Roivant, a new therapeutic drug for schizophrenia under development, SEP-363856, has entered phase III trials in the United States. In Japan, we have steadily proceeded with development toward market launch, including a successful completion of the phase III trials of the antidiabetic drug Imeglimin.

Performance targets in FY2021

Assuming an exchange rate of 110 yen/\$ and a naphtha price of 51,000 yen/kiloliter as well as other factors in the business environment outlook at the time of planning, we are aiming for sales revenue of 2,950 billion yen, core operating income of 280 billion yen, and net income attributable to owners of the parent of 150 billion yen as performance targets for FY2021, the final year of the Corporate Business Plan.

Business environment and future performance outlook

The business environment surrounding the Group was subject to many headwinds such as the global economic slowdown associated with prolonged US-China trade friction alongside unfavorable weather conditions in Japan and overseas. As a result, for FY2019, the first year of the Corporate Business Plan, net income attributable to owners of the parent decreased by 74% year-on-year to ¥30.9 billion, resulting in a severe outcome.

Regarding the business environment in the future, amid the serious adverse effects on the global economy due to the explosive spread of COVID-19, we do not anticipate a quick recovery in our business results in FY2020 due to a sluggish product market in the Petrochemicals & Plastics Sector as well as an increase in R&D expenses, etc. accrued in advance in association with strategic investment in the Pharmaceuticals Sector.

Under such a difficult business environment, for FY2021, the final year of the Corporate Business Plan, it is not easy to achieve the initially specified performance targets. However, by making a company-wide effort to tackle various issues, we will strive to recover as soon as possible in terms of business performance levels and financial structure.

In the medium to long term, we aim to stably achieve financial indicators such as an ROE of 10% or more, ROI of 7% or more, and a D/E ratio of approximately 0.7 times.

(3) Assets and Income

1) Trends in assets and income of the Group

Item	The 136th term (April 1, 2016 to March 31, 2017)	The 137th term (April 1, 2017 to March 31, 2018)	The 138th term (April 1, 2018 to March 31, 2019)	The 139th term (April 1, 2019 to March 31, 2020)
Japanese GAAP				
Net sales (Billions of yen)	1,954.3			
Ordinary income (Billions of yen)	166.6			
Net income attributable to owners of the parent (Billions of yen)	85.5			
Net income per share	52.30 yen			
ROE	10.8%			
Net assets (Billions of yen)	1,162.5			
Total assets (Billions of yen)	2,851.7			
IFRS				
Sales revenue (Billions of yen)	1,939.1	2,190.5	2,318.6	2,225.8
Core operating income (Billions of yen)	184.5	262.7	204.3	132.7
Net income attributable to owners of the parent (Billions of yen)	76.5	133.8	118.0	30.9
Basic earnings per share	46.81 yen	81.81 yen	72.17 yen	18.91 yen
ROE	9.8%	15.4%	12.3%	3.2%
Equity attributable to owners of the parent (Billions of yen)	812.6	927.1	998.7	922.3
Total equity (Billions of yen)	1,115.9	1,252.2	1,351.9	1,388.8
Total assets (Billions of yen)	2,878.2	3,068.7	3,171.6	3,650.3

NOTE: In connection with the confirmation in the 137th Fiscal Period of provisional accounting procedures relating to the business combination that took place in the 136th Fiscal Period, retrospective adjustments have been made to figures for the 136th period due to purchase price allocation changes.

2) Trends in assets and income of the Company

Item	The 136th term (April 1, 2016 to March 31, 2017)	The 137th term (April 1, 2017 to March 31, 2018)	The 138th term (April 1, 2018 to March 31, 2019)	The 139th term (April 1, 2019 to March 31, 2020)
Japanese GAAP				
Net sales (Billions of yen)	650.9	708.4	723.6	678.4
Ordinary income (Billions of yen)	58.0	75.9	73.7	28.9
Net income (Billions of yen)	36.9	55.8	67.0	22.8
Net income per share	22.54 yen	34.15 yen	40.96 yen	13.94 yen
Net assets (Billions of yen)	295.2	327.2	350.3	315.5
Total assets (Billions of yen)	1,373.9	1,456.0	1,496.4	1,577.2

NOTE: “Partial Amendments to Accounting Standard for Tax Effect Accounting, etc.” (Accounting Standards Board of Japan (ASBJ) Statement No. 28; February 16, 2018) have been applied from the 138th Fiscal Period, and have been retrospectively applied to the figures for the 137th Fiscal Period.

(4) Principal Businesses (as of March 31, 2020)

Business sector	Key products and businesses
Petrochemicals & Plastics	Petrochemical products, inorganic chemicals, raw materials for synthetic fibers, organic chemicals, synthetic resins, methyl methacrylate products, synthetic resin processed products, etc.
Energy & Functional Materials	Alumina products, aluminum, specialty chemicals, additives, dyestuffs, synthetic rubber, engineering plastics, battery materials, etc.
IT-related Chemicals	Optical products, color filters, semiconductor processing materials, compound semiconductor materials, touchscreen panels, etc.
Health & Crop Sciences	Crop protection chemicals, fertilizers, agricultural materials, household and public hygiene insecticides, materials for protection against tropical diseases, feed additives, pharmaceutical chemicals, etc.
Pharmaceuticals	Pharmaceuticals for medical treatment, radiopharmaceuticals, etc.

Aside from the above, as “Others”, the Group supplies electric power and steam, designs chemical plants/supervises the construction of those facilities, provides transportation and warehousing, and conducts physical property analysis/environmental analysis, etc.

(5) Principal Business Locations (as of March 31, 2020)

1) The Company

Head offices	Tokyo, Osaka
Branch offices	Tokyo, Osaka, Nagoya Branch Office, Fukuoka Branch Office
Plants	Ehime Works, Chiba Works, Osaka Works, Ohe Works (Ehime), Oita Works, Misawa Works (Aomori)
Research laboratories	Industrial Technology & Research Laboratory (Osaka), Environmental Health Science Laboratory (Osaka), Advanced Materials Development Laboratory (Ibaraki), Bioscience Research Laboratory (Osaka)

- NOTES: 1 Oita Works includes Okayama Plant and Gifu Plant.
2 Research laboratories are shown as corporate research facilities. There also exist business sector research laboratories, such as the Health & Crop Sciences Research Laboratory (Hyogo), etc.

2) Material subsidiaries

Domestic	Sumitomo Dainippon Pharma Co., Ltd. (Osaka, Tokyo, Mie, Oita) Tanaka Chemical Corporation (Fukui, Osaka) Koei Chemical Co., Ltd. (Chiba, Tokyo) Taoka Chemical Co., Ltd. (Osaka, Hyogo, Ehime)
Overseas	United States Sumitomo Chemical America, Inc. Valent U.S.A. LLC Valent BioSciences LLC Sunovion Pharmaceuticals Inc. Boston Biomedical, Inc.
	Brazil Sumitomo Chemical do Brasil Representações Ltda
	Chile Sumitomo Chemical Chile S.A.
	United Kingdom Cambridge Display Technology Limited
	Switzerland Urovant Sciences GmbH Myovant Sciences GmbH
	India Sumitomo Chemical India Limited
	Singapore Sumitomo Chemical Asia Pte Ltd The Polyolefin Company (Singapore) Pte. Ltd.
	South Korea Dongwoo Fine-Chem Co., Ltd. SSLM Co., Ltd.
	Taiwan Sumika Technology Co., Ltd.
	China XUYOU Electronic Materials (Wuxi) Co., Ltd. Sumika Electronic Materials (Wuxi) Co., Ltd.

(6) Status of material subsidiaries (as of March 31, 2020)

Company name	Capital	Ratio of voting rights (%)	Principal business
Sumitomo Chemical America, Inc.	USD 510,092 thousand	100.00	Investment in related companies in the United States and sale of chemical products
Valent U.S.A. LLC	USD 242,574 thousand	100.00 (100.00)	Development and sale of plant protection, etc.
Valent BioSciences LLC	USD 129,344 thousand	100.00 (100.00)	Research, development, manufacture and sale of biorational
Sumika Polymers America Corp.	USD 222,544 thousand	100.00 (100.00)	—
Sumitomo Chemical do Brasil Representações Ltda	BRL 2,320,990 thousand	100.00	Development, promotion and sales of crop protection chemicals, feed additives and household & public hygiene insecticides
CDT Holdings Limited	GBP 187,511 thousand	100.00	Investment in Cambridge Display Technology Limited
Cambridge Display Technology Limited	GBP 183,716 thousand	100.00 (100.00)	R&D and licenses in polymer organic light emitting diodes and devices
Dongwoo Fine-Chem Co., Ltd.	KRW 283,876 million	100.00	Manufacture and sale of process chemicals for semiconductors and displays, optical functional films, touchscreen panels, color filters, etc.
SSLM Co., Ltd.	KRW 280,000 million	100.00	Manufacture and sale of heat-resistant separators
Japan-Singapore Petrochemicals Co., Ltd.	JPY 23,877 million	79.67	Investment in Petrochemical Corporation of Singapore (Pte.) Ltd.
Sumitomo Dainippon Pharma Co., Ltd.	JPY 22,400 million	51.78	Manufacture and sale of pharmaceuticals
Sumitomo Dainippon Pharma America, Inc.	USD 2,170,480 thousand	100.00 (100.00)	Investment in related companies in the United States
Sunovion Pharmaceuticals Inc.	USD 1,710,032 thousand	100.00 (100.00)	Manufacture and sale of pharmaceuticals
Boston Biomedical, Inc.	USD 380,484 thousand	100.00 (100.00)	Research and development of pharmaceuticals
Sumitovant Biopharma Ltd.	USD 140,000 thousand	100.00 (100.00)	Investment in affiliated companies conducting research and development of pharmaceuticals
Myovant Sciences Ltd.	USD 614,501 thousand	50.00 (50.00)	Investment in affiliated companies conducting research and development of pharmaceuticals
Myovant Holdings Limited	USD 480,252 thousand	100.00 (100.00)	Investment in affiliated companies conducting research and development of pharmaceuticals

Company name	Capital	Ratio of voting rights (%)	Principal business
Myovant Sciences GmbH	USD 481,216 thousand	100.00 (100.00)	Research and development of pharmaceuticals
Urovant Sciences Ltd.	USD 245,699 thousand	75.00 (75.00)	Investment in affiliated companies conducting research and development of pharmaceuticals
Urovant Holdings Limited	USD 282,084 thousand	100.00 (100.00)	Investment in affiliated companies conducting research and development of pharmaceuticals
Urovant Sciences GmbH	USD 281,755 thousand	100.00 (100.00)	Research and development of pharmaceuticals
Enzyvant Therapeutics Ltd.	USD 142,925 thousand	100.00 (100.00)	Investment in affiliated companies conducting research and development of pharmaceuticals
Enzyvant Therapeutics General Ltd.	USD 136,683 thousand	100.00 (100.00)	Investment in affiliated companies conducting research and development of pharmaceuticals
Enzyvant Therapeutics Holdings Limited	USD 128,189 thousand	100.00 (100.00)	Investment in affiliated companies conducting research and development of pharmaceuticals
XUYOU Electronic Materials (Wuxi) Co., Ltd.	RMB 1,115,757 thousand	98.00 (55.00)	Manufacture and sale of optical functional films
Sumika Electronic Materials (Wuxi) Co., Ltd.	RMB 1,276,517 thousand	100.00 (10.00)	Processing and sale of optical functional films
Sumika Technology Co., Ltd.	TWD 4,417 million	84.96	Manufacture and sale of original fabrics and processed products of optical functional films, and color filters
Sumitomo Chemical Asia Pte Ltd	USD 150,565 thousand	100.00	Manufacture and sale of petrochemical products, etc. and supervision of the Sumitomo Chemical Group in the Southeast Asia, India, and Oceania area
The Polyolefin Company (Singapore) Pte. Ltd.	USD 51,690 thousand	70.00 (70.00)	Manufacture and sale of low-density polyethylene and polypropylene
Sumitomo Chemical Chile S.A.	USD 85,486 thousand	100.00	Registration and sales of crop protection chemicals, sales of feed additives and others
Tanaka Chemical Corporation	JPY 9,155 million	50.45	Manufacturing and sale of positive electrode materials for rechargeable batteries and positive electrode material intermediate, etc.

Company name	Capital	Ratio of voting rights (%)	Principal business
Sumitomo Chemical India Limited	INR 2,745,881 thousand	80.30	Development and sales of crop protection products, household & public hygiene insecticides and feed additives, and manufacturing of crop protection chemicals
Koei Chemical Co., Ltd.	JPY 2,343 million	56.33 (0.45)	Manufacture and sale of chemical products, pharmaceutical and crop protection intermediates, etc.
Taoka Chemical Co., Ltd.	JPY 1,572 million	51.55 (0.78)	Manufacture and sale of intermediates for dyestuffs and pharmaceutical and crop protection, functional materials, etc.

From the fiscal year under review, Sumitomo Chemical do Brasil Representações Ltda, Sumitovant Biopharma Ltd., Myovant Sciences Ltd., Myovant Holdings Limited, Myovant Sciences GmbH, Urovant Sciences Ltd., Urovant Holdings Limited, Urovant Sciences GmbH, Enzyvant Therapeutics Ltd., Enzyvant Therapeutics General Ltd., Enzyvant Therapeutics Holdings Limited, and Sumitomo Chemical Chile S.A. are listed as material subsidiaries.

Sumika Polymers America Corp. made investment in Phillips Sumika Polypropylene Company, which has been dissolved.

Dalian Sumika Jingang Chemicals Co., Ltd., which was listed in the previous fiscal year, has been removed from material subsidiaries as its materiality was decreased.

Excel Crop Care Limited, which was listed in the previous fiscal year, has disappeared as it was merged with Sumitomo Chemical India Limited.

- NOTES: 1 Figures contained in parentheses () for ratio of voting rights are the ratio of voting rights held by subsidiaries of the Company.
- 2 Capital for Sumitomo Chemical America, Inc., CDT Holdings Limited, Cambridge Display Technology Limited, Sumitomo Dainippon Pharma America, Inc., Sunovion Pharmaceuticals Inc., Boston Biomedical, Inc., Sumitovant Biopharma Ltd., Myovant Sciences Ltd., Myovant Holdings Limited, Myovant Sciences GmbH, Urovant Sciences Ltd., Urovant Holdings Limited, Urovant Sciences GmbH, Enzyvant Therapeutics Ltd., Enzyvant Therapeutics General Ltd., and Enzyvant Therapeutics Holdings Limited are shown as paid-in capital.

(7) Employees (as of March 31, 2020)

1) Employees of the Group

Business category	Number of employees (Persons)	Notes
Petrochemicals & Plastics	4,605	
Energy & Functional Materials	2,972	
IT-related Chemicals	8,039	
Health & Crop Sciences	6,727	
Pharmaceuticals	7,272	
Others	2,821	
Companywide shared	1,150	
Total	33,586	The number of employees increased by 1,044 persons year-on-year.

NOTE: The number of employees does not include employees who are temporary, part-time, contracted, or seconded outside of consolidated subsidiaries.

2) Employees of the Company

Number of employees	Average age	Average years of employment	Notes
persons		years	
6,214	40.9	15.3	The number of employees increased by 118 persons year-on-year.

NOTE: The number of employees does not include employees who are temporary, part-time, contracted, or seconded to other companies.

(8) Primary sources of borrowings and amounts (as of March 31, 2020)

Source of borrowing	Amount of borrowing (Balance) (Billions of yen)
Sumitomo Mitsui Banking Corporation	328.3
Development Bank of Japan Inc.	44.0
MUFG Bank, Ltd.	29.9
The Norinchukin Bank	21.1
Sumitomo Mitsui Trust Bank, Limited	17.0

NOTES: 1 The amount of borrowing listed above includes loans from overseas subsidiaries of the sources.

2 Aside from the above, there are 249.0 billion yen in borrowings as syndicated loans, managed by financial institutions such as the Sumitomo Mitsui Banking Corporation.

2. Status of Shares (as of March 31, 2020)

- (1) **Total number of shares authorized to be issued** 5,000,000,000 shares
- Total number of shares outstanding** 1,655,446,177 shares
(including 20,445,812 shares of the Company's treasury shares)
- (2) **Number of shareholders** 147,417 persons
- (3) **Major shareholders**

Shareholder name	Number of shares	Shareholding ratio
	thousand shares	%
The Master Trust Bank of Japan, Ltd. (Trust account)	127,165	7.77
Japan Trustee Services Bank, Ltd. (Trust account)	96,698	5.91
Sumitomo Life Insurance Company	71,000	4.34
Nippon Life Insurance Company	41,031	2.50
Japan Trustee Services Bank, Ltd. (Trust account 7)	37,145	2.27
Japan Trustee Services Bank, Ltd. (Trust account 4)	31,756	1.94
Japan Trustee Services Bank, Ltd. (Trust account 5)	29,355	1.79
JP MORGAN CHASE BANK 385151	29,106	1.78
Japan Trustee Services Bank, Ltd. (Master trust for the Sumitomo Mitsui Trust Bank and trust account for retirement benefits for Sumitomo Life Insurance Company)	29,000	1.77
SSBTC CLIENT OMNIBUS ACCOUNT	26,476	1.61

NOTE: The Company's treasury shares (20,445,812 shares) were excluded in the calculation of the percentage of shares held.

3. Company Officers

(1) Directors and Corporate Auditors (as of March 31, 2020)

Position	Name	Areas of responsibility and significant concurrent positions
Representative Director, Chairman	Masakazu Tokura	
Representative Director, President (Concurrently serving as Executive President)	Keiichi Iwata	
Representative Director (Concurrently serving as Executive Vice President)	Ray Nishimoto	Supervision of Health & Crop Sciences Sector Chairman of Valent U.S.A. LLC Chairman of Valent BioSciences LLC Chairman of Vector Health International Ltd.
Representative Director (Concurrently serving as Senior Managing Executive Officer)	Noriaki Takeshita	Supervision of Rabigh Project, Petrochemicals & Plastics Sector Deputy Chairman of Rabigh Refining and Petrochemical Company
*Representative Director (Concurrently serving as Managing Executive Officer)	Masaki Matsui	Supervision of IT-related Chemicals Sector, PLED Business Planning, Electronic Devices Development Center Chairman of Sumika Technology Co., Ltd.
*Representative Director (Concurrently serving as Managing Executive Officer)	Kingo Akahori	Supervision of Energy & Functional Materials Sector
Director (Concurrently serving as Executive Vice President)	Hiroshi Ueda	Supervision of Research Planning and Coordination, Digital and Data Science Innovation, Process & Production Technology & Safety Planning, Production & Safety Fundamental Technology Center, Intellectual Property, Responsible Care, Industrial Technology & Research Laboratory, Environmental Health Science Laboratory, Advanced Materials Development Laboratory, Bioscience Research Laboratory
Director (Concurrently serving as Senior Managing Executive Officer)	Hiroshi Niinuma	Supervision of General Affairs, Legal, CSR, Internal Control and Audit, Human Resources, Osaka Office Administration, Corporate Communications, Procurement, Logistics Outside Director of Sumitomo Seika Chemicals Co., Ltd.

Position	Name	Areas of responsibility and significant concurrent positions
*Director (Concurrently serving as Senior Managing Executive Officer)	Takashi Shigemori	Supervision of Corporate Business Development, Corporate Planning, IT Innovation, Accounting, Finance Director of Rabigh Refining and Petrochemical Company President of Japan-Singapore Petrochemicals Co., Ltd.
Director (Outside Director, Independent Officer)	Koichi Ikeda	Adviser of Asahi Group Holdings, Ltd.
Director (Outside Director, Independent Officer)	Hiroshi Tomono	Adviser of NIPPON STEEL CORPORATION Outside Director of Japan Nuclear Fuel Limited
Director (Outside Director, Independent Officer)	Motoshige Itoh	Professor, Faculty of International Social Sciences, Gakushuin University Outside Director of East Japan Railway Company Outside Director of THE SHIZUOKA BANK, LTD. Outside Corporate Auditor of Hagoromo Foods Corporation
Director (Outside Director, Independent Officer)	Atsuko Muraki	Outside Member of the Board of ITOCHU Corporation Outside Director of Sompo Holdings, Inc.
*Standing Corporate Auditor	Kunio Nozaki	
Standing Corporate Auditor	Hiroaki Yoshida	Outside Corporate Auditor of Sumitomo Seika Chemicals Co., Ltd.
Corporate Auditor (Outside Corporate Auditor, Independent Officer)	Mitsuhiro Aso	Attorney External Director of Sumitomo Mitsui Trust Holdings, Inc.
Corporate Auditor (Outside Corporate Auditor, Independent Officer)	Yoshitaka Kato	Certified Public Accountant Outside Corporate Auditor of Mitsui Fudosan Co., Ltd. Outside Corporate Auditor of Sumitomo Corporation
Corporate Auditor (Outside Corporate Auditor, Independent Officer)	Michio Yoneda	Outside Director of Kawasaki Heavy Industries, Ltd. Outside Director of Asahi Broadcasting Group Holdings Corporation Outside Director of Toyo Tire Corporation

- NOTES: 1 Of the Directors, Mr. Koichi Ikeda, Mr. Hiroshi Tomono, Mr. Motoshige Itoh, and Ms. Atsuko Muraki are Outside Directors.
- 2 Of the Corporate Auditors, Mr. Mitsuhiro Aso, Mr. Yoshitaka Kato, and Mr. Michio Yoneda are Outside Corporate Auditors.
- 3 Directors and Corporate Auditors marked with an asterisk (*) were newly elected at

the 138th Ordinary General Meeting of Shareholders held on June 21, 2019, and assumed office.

- 4 The Company has designated Mr. Koichi Ikeda, Mr. Hiroshi Tomono, Mr. Motoshige Itoh, Ms. Atsuko Muraki, Mr. Mitsuhiro Aso, Mr. Yoshitaka Kato, and Mr. Michio Yoneda as Independent Directors / Auditors pursuant to the regulations of the Tokyo Stock Exchange, Inc. and has made notification to said Exchange.
- 5 Corporate Auditor Yoshitaka Kato is qualified as a certified public accountant, and has a significant amount of knowledge regarding finance and accounting.
- 6 Of the significant concurrent positions served by Outside Directors and Outside Corporate Auditors, although ITOCHU Corporation, Sumitomo Mitsui Trust Holdings, Inc., Sumitomo Corporation, and Toyo Tire Corporation have transactions with the Company, there are no special interests with the Company, and there are no transactional relationships with any other parties served as significant concurrent positions.
- 7 Directors and Corporate Auditors who retired in the fiscal year under review are as follows.

Position at time of retirement	Name	Areas of responsibility and significant concurrent positions at time of retirement
Director	Osamu Ishitobi	
Director	Toshihisa Deguchi	
Director	Kunio Nozaki	
Corporate Auditor	Kenya Nagamatsu	Outside Corporate Auditor of Sumitomo Seika Chemicals Co., Ltd.

(Retired on June 21, 2019 because of the expiration of the terms of office.)

- 8 Positions, areas of responsibility and significant concurrent positions for Directors and Corporate Auditors as of April 1, 2020 are as follows.

Position	Name	Areas of responsibility and significant concurrent positions
Representative Director, Chairman	Masakazu Tokura	
Representative Director, President (Concurrently serving as Executive President)	Keiichi Iwata	
Representative Director (Concurrently serving as Senior Managing Executive Officer)	Noriaki Takeshita	Supervision of Petrochemicals & Plastics Sector Deputy Chairman of Rabigh Refining and Petrochemical Company
Representative Director (Concurrently serving as Managing Executive Officer)	Masaki Matsui	Supervision of IT-related Chemicals Sector, PLED Business Planning, Electronic Devices Development Center
Representative Director (Concurrently serving as Managing Executive Officer)	Kingo Akahori	Supervision of Energy & Functional Materials Sector
Director	Ray Nishimoto	

Position	Name	Areas of responsibility and significant concurrent positions
Director (Concurrently serving as Executive Vice President)	Hiroshi Ueda	Supervision of Research Planning and Coordination, Digital and Data Science Innovation, Process & Production Technology & Safety Planning, Production & Safety Fundamental Technology Center, Intellectual Property, Responsible Care, Industrial Technology & Research Laboratory, Environmental Health Science Laboratory, Advanced Materials Development Laboratory, Bioscience Research Laboratory
Director (Concurrently serving as Senior Managing Executive Officer)	Hiroshi Niinuma	Supervision of General Affairs, Legal, Sustainability, Internal Control and Audit, Human Resources, Osaka Office Administration, Corporate Communications, Procurement, Logistics Outside Director of Sumitomo Seika Chemicals Co., Ltd.
Director (Concurrently serving as Senior Managing Executive Officer)	Takashi Shigemori	Supervision of Corporate Planning, IT Innovation Director of Rabigh Refining and Petrochemical Company President of Japan-Singapore Petrochemicals Co., Ltd.
Director (Outside Director, Independent Officer)	Koichi Ikeda	Adviser of Asahi Group Holdings, Ltd.
Director (Outside Director, Independent Officer)	Hiroshi Tomono	Adviser of NIPPON STEEL CORPORATION Outside Director of Japan Nuclear Fuel Limited
Director (Outside Director, Independent Officer)	Motoshige Itoh	Professor, Faculty of International Social Sciences, Gakushuin University Outside Director of East Japan Railway Company Outside Director of THE SHIZUOKA BANK, LTD. Outside Corporate Auditor of Hagoromo Foods Corporation
Director (Outside Director, Independent Officer)	Atsuko Muraki	Outside Member of the Board of ITOCHU Corporation Outside Director of Sampo Holdings, Inc.
Standing Corporate Auditor	Kunio Nozaki	

Position	Name	Areas of responsibility and significant concurrent positions
Standing Corporate Auditor	Hiroaki Yoshida	Outside Corporate Auditor of Sumitomo Seika Chemicals Co., Ltd.
Corporate Auditor (Outside Corporate Auditor, Independent Officer)	Mitsuhiro Aso	Attorney External Director of Sumitomo Mitsui Trust Holdings, Inc.
Corporate Auditor (Outside Corporate Auditor, Independent Officer)	Yoshitaka Kato	Certified Public Accountant Outside Corporate Auditor of Mitsui Fudosan Co., Ltd. Outside Corporate Auditor of Sumitomo Corporation
Corporate Auditor (Outside Corporate Auditor, Independent Officer)	Michio Yoneda	Outside Director of Kawasaki Heavy Industries, Ltd. Outside Director of Asahi Broadcasting Group Holdings Corporation Outside Director of Toyo Tire Corporation

(2) Compensation to Directors and Corporate Auditors

1) Policies and procedures for determining compensation of Senior Management and Directors

(A) Basic policy for remunerations of Directors, etc.

- i. The remunerations of senior management and directors (hereinafter “Directors etc.”) shall consist of Basic Compensation and Bonuses.
- ii. Basic Compensation is designed to serve as an incentive for the actions of Directors, etc. to contribute to the Company’s sustainable growth, rather than aiming for short-term or sub-optimal effects.
- iii. The amount of Bonuses shall largely reflect the Company's consolidated financial results for a fiscal year in order to heighten incentive to achieve the annual target of the business plans.
- iv. The remuneration shall be set at levels which are designed to be objectively competitive to attract and retain outstanding talent while taking into consideration such factors as the scale and content of the Company’s business. Based on surveys by a third-party organization and other materials, such levels shall be checked annually whether or not to be objectively appropriate.

(B) Mechanisms of each remuneration element (Please refer to the following conceptual diagram of the Remunerations of Directors.)

i. Basic Compensation

The level of Basic Compensation shall be determined based on the policy described in section (A) iv above.

While Basic Compensation for each year shall be fixed, the Company will adopt a mechanism where the Basic Compensation level would be changed in the event where the Company’s position has changed in terms of “company’s size,” “earnings capacity,” and “outside evaluations” from a comprehensive and medium- to long-term perspective.

As main indicators for determining the change in the Company position, the Company will apply the following: 1) in terms of “company’s size,” sales revenue, total assets and market capitalization, 2) in terms of “earnings capacity,” net income (attributable to the parent company), ROE, ROI and D/E ratio, and 3) in terms of “outside evaluations,” credit ratings and ESG index selected by GPIF (Government Pension Investment Fund).

The amounts to be paid to each person will be determined in accordance with the base amount set by each position.

ii. Bonuses


Bonuses shall be paid on the condition that performance for that fiscal year exceeds a particular level and shall be determined based on the bonus calculation formula (performance indicator × coefficient).

In order to reflect the current earnings capacity of the relevant business year (including financial activities) to the amount of bonuses, the Company will apply the combined value of consolidated core operating profit and financial profit and loss to the performance indicator concerning the bonus calculation formula. In addition, the Company will set the coefficient of the calculation formula so that it will get larger as the position of a person gets higher.

iii. Percentages of fixed remuneration (Basic Compensation) and performance-linked remuneration (Bonuses)

The Company will design the bonus calculation formula so that the bonuses of Directors (excluding Outside Directors) accounts for roughly 30% of the remuneration when the consolidated performance goal (core operating profit) for the latest fiscal year of the Corporate Business Plan (fiscal years 2019 to 2021) is achieved.

(Conceptual diagram of the Remunerations of Directors)



Based on the factors for determination described below, the Company will change the amount of remuneration when it is determinable that the Company's position has changed from a comprehensive and medium- to long-term perspective.

Factors for Determination	Major Indicators
Company's Size	Sales revenue
	Total assets
	Market capitalization
Earnings Capacity	Current income (attributable to the parent company)
	ROE
	ROI
	D/E ratio
Outside Evaluations	Credit ratings
	ESG index selected by GPIF

The amount of bonuses will be determined by the calculation formula based on the following consolidated performance indicator.

Consolidated Performance Indicator	Core operating profit plus Financial profit and loss			
Calculation Formula	consolidated performance indicator	×	coefficient*2	

*2 The Company will arrange so that the higher the position, the larger the coefficient will be.

(Note) If a consolidated performance indicator does not exceed a particular level, bonuses will not be paid.

(Note) The amount to be paid to each person will be determined by each position.

(C) Procedures for determining remunerations of Directors, etc.

The Company shall establish a Remuneration Advisory Committee as an advisory body to the Board of Directors on a remuneration system for Directors, etc., levels of remuneration, and other matters incidental thereto. Composed mainly of Outside Officers, the Committee shall advise the Board of Directors about the remuneration system for Directors, etc., levels of remuneration, etc. so that greater transparency and fairness can be ensured regarding the remuneration.

The remuneration amount of Directors shall be set at a level not higher than the upper limit of a total remuneration prescribed by the resolution of the 125th General Meeting of Shareholders held on June 23, 2006 (i.e., 1.0 billion yen or less per year).

The Board of Directors shall deliberate on and decide the method of determining remunerations of Directors, etc., based on the advice from the Remuneration Advisory Committee. Furthermore, the specific amount of remuneration for each Director, etc. shall be determined by the Director and Chairman authorized by the Board of Directors, based on the standard advised from the Remuneration Advisory Committee.

2) Total amount of compensation to Directors and Corporate Auditors for the fiscal year under review

Category	Number of persons	Amount of compensation
Directors (Of which, Outside Directors)	16 persons (4 persons)	715 million yen (66 million yen)
Corporate Auditors (Of which, Outside Corporate Auditors)	6 persons (3 persons)	116 million yen (37 million yen)
Total	22 persons	831 million yen

- NOTES: 1. The above number of persons and amount of compensation includes three Directors and one Corporate Auditor who retired during the fiscal year under review.
2. Due to a resolution by a General Meeting of Shareholders, the total amount of compensation for Directors is 1.0 billion yen or less per annum, and the total amount of compensation for Corporate Auditors is 150.00 million yen or less per annum (resolved at the 125th Ordinary General Meeting of Shareholders held on June 23, 2006).

(Reference)

Executive Officers (excluding persons concurrently serving as Directors) are as follows.

(As of April 1, 2020)

Position	Name	Areas of responsibility
Managing Executive Officer	Marc Vermeire	Engaged in Sumitomo Chemical Europe, Sumitomo Chemical Agro Europe
Managing Executive Officer	Keiichi Sakata	In charge of Corporate Planning Office, General Manager of Corporate Planning Office
Managing Executive Officer	Motoyuki Sakai	Engaged in Sumitomo Chemical Asia
Managing Executive Officer	Yoshiaki Oda	In charge of Corporate Planning Office, Intellectual Property Dept., General Manager of Corporate Planning Office
Managing Executive Officer	Nobuaki Mito	Supervision of Health & Crop Sciences Sector
Managing Executive Officer	Soji Sakamoto	In charge of Basic Materials Div., Industrial Chemicals Div., Resin-related Business Development Dept., Polyolefins Div., Automotive Materials Div.
Managing Executive Officer	Yoshihiro Miyoshi	In charge of Digital and Data Science Innovation Dept., Process & Production Technology & Safety Planning Dept., Production & Safety Fundamental Technology Center, Responsible Care Dept.

Position	Name	Areas of responsibility
Managing Executive Officer	Seiji Takeuchi	In charge of Planning & Coordination Office, Petrochemicals & Plastics Sector, Responsible Care Dept., Petrochemicals & Plastics Sector, Petrochemicals Research Laboratory
Managing Executive Officer	Naoyuki Inoue	Engaged in Rabigh Refining and Petrochemical Company
Managing Executive Officer	Yasuaki Sasaki	In charge of Inorganic Materials Div., Advanced Polymers Div.
Managing Executive Officer	Keigo Sasaki	Supervision of Accounting, Finance, in charge of Corporate Communications Dept.
Managing Executive Officer	Kenji Ohno	In charge of General Affairs Dept., Legal Dept., Sustainability Dept., Internal Control & Audit Dept.
Executive Officer	Andrew Lee	Engaged in Valent U.S.A., Valent BioSciences
Executive Officer	Shinichiro Nagata	In charge of Ehime Works, General Manager of Ehime Works
Executive Officer	Yoshizumi Sasaki	In charge of Resin-related Business Development Dept., Polyolefins Div., Automotive Materials Div., General Manager of Automotive Materials Div.
Executive Officer	Ichiro Kosaka	In charge of Planning & Coordination Office, Energy & Functional Materials Sector, Specialty Chemicals Div.
Executive Officer	Masaya Naito	In charge of Procurement Dept., Logistics Dept.
Executive Officer	Takanari Yamaguchi	In charge of PLED Business Planning Office, Planning & Coordination Office, IT-related Chemicals Sector, Optical Materials Div.
Executive Officer	Akira Iwasaki	In charge of Planning & Coordination Office, Energy & Functional Materials Sector, General Manager of Planning & Coordination Office, Energy & Functional Materials Sector
Executive Officer	Hirokazu Murata	In charge of Oita Works, Misawa Works, General Manager of Oita Works

Position	Name	Areas of responsibility
Executive Officer	Isao Kurimoto	In charge of Research Planning and Coordination Dept., Digital and Data Science Innovation Dept., Industrial Technology & Research Laboratory
Executive Officer	Koichi Ogino	In charge of Chiba Works, General Manager of Chiba Works
Executive Officer	Kimitoshi Umeda	In charge of AgroSolutions Div.- International, Environmental Health Div.
Executive Officer	Inho Rha	Engaged in Dongwoo Fine-Chem
Executive Officer	Akira Nakanishi	In charge of Planning & Coordination Office, IT-related Chemicals Sector, Quality Assurance Office, IT-related Chemicals Sector, General Manager of Planning & Coordination Office, IT-related Chemicals Sector
Executive Officer	Masao Shimizu	In charge of Human Resources Dept., Osaka Office Administration Dept., General Manager of Human Resources Dept.
Executive Officer	Hiroaki Fujimoto	In charge of AgroSolutions Div.- Japan, General Manager of AgroSolutions Div.- Japan
Executive Officer	Kanako Fukuda	Engaged in Sumitomo Chemical Europe
Executive Officer	Juan Ferreira	Engaged in Sumitomo Chemical do Brasil Representações Ltda
Executive Officer	Hiroyoshi Mukai	In charge of Planning & Coordination Office, Health & Crop Sciences Sector, Quality Assurance Office, Health & Crop Sciences Sector, General Manager of Planning & Coordination Office, Health & Crop Sciences Sector

4. Outside Officers

(1) Main activities during the fiscal year under review

Title	Name	Main activities
Outside Director	Koichi Ikeda	Mr. Koichi Ikeda attended all 13 Board of Directors meetings held during the fiscal year under review, and commented as required primarily from an experienced management perspective.
	Hiroshi Tomono	Mr. Hiroshi Tomono attended all 13 Board of Directors meetings held during the fiscal year under review, and commented as required primarily from an experienced management perspective.
	Motoshige Itoh	Mr. Motoshige Itoh attended 12 meetings out of 13 Board of Directors meetings held during the fiscal year under review, and commented as required primarily based on his expert knowledge of economics, etc. as a university professor and abundant experience deriving from his track record as a member of various government deliberative committees.
	Atsuko Muraki	Ms. Atsuko Muraki attended 12 meetings out of 13 Board of Directors meetings held during the fiscal year under review, and commented as required primarily based on her wealth of experience and extensive knowledge in legal, social and other issues deriving from her employment at administrative bodies as a civil servant.
Outside Corporate Auditor	Mitsuhiro Aso	Mr. Mitsuhiro Aso attended all 13 Board of Directors meetings and all 14 Board of Corporate Auditors meetings held during the fiscal year under review, and commented as required primarily from a specialized viewpoint as an attorney.
	Yoshitaka Kato	Mr. Yoshitaka Kato attended all 13 Board of Directors meetings and all 14 Board of Corporate Auditors meetings held during the fiscal year under review, and commented as required primarily from a specialized viewpoint as a certified public accountant.
	Michio Yoneda	Mr. Michio Yoneda attended 12 meetings out of 13 Board of Directors meetings and 13 meetings out of 14 Board of Corporate Auditors meetings held during the fiscal year under review, and commented as required primarily from his experienced management perspective in financial and securities markets.

(2) Summary of the limitation of liability contracts

The Company has concluded limitation of liability contracts with each Outside Officer that limit their liabilities for damages to the Company pursuant to Article 423(1) of the Companies Act, up to the total of the amounts listed in the items of Article 425(1) of the Companies Act, provided that the execution of duties by Outside Officers were in good faith and without gross negligence.

5. Accounting Auditor

(1) Accounting Auditor's name

KPMG AZSA LLC

(2) Accounting Auditor's compensation, etc. for the fiscal year under review

Content	Compensation
Amount of compensation, etc.	157 million yen
Cash and other profits payable by the Company or its subsidiaries to Accounting Auditor	449 million yen

- NOTES: 1 Under the audit agreement between the Company and its Accounting Auditor, compensation for audits pursuant to the Companies Act and audits pursuant to the Financial Instruments and Exchange Act are not strictly separated, and cannot be separated. Consequently, the above amount of compensation, etc., reflects total compensation for audits pursuant to the Financial Instruments and Exchange Act.
- 2 The Board of Corporate Auditors has evaluated and confirmed the content of the Accounting Auditor's audit plan, status of execution of duties, and basis for calculating compensation estimates, and as a result of comprehensive consideration to the appropriateness of audit compensation, has provided approval to the compensation, etc., of the Accounting Auditor pursuant to Article 399(1) of the Companies Act.
- 3 Of the Company's material subsidiaries, Sumitomo Chemical do Brasil Representações Ltda, CDT Holdings Limited, Cambridge Display Technology Limited, Dongwoo Fine-Chem Co., Ltd., SSLM Co., Ltd., Myovant Sciences Ltd., Myovant Holdings Limited, Myovant Sciences GmbH, Urovant Sciences Ltd., Urovant Holdings Limited, XUYOU Electronic Materials (Wuxi) Co., Ltd., Sumika Electronic Materials (Wuxi) Co., Ltd., Sumika Technology Co., Ltd., Sumitomo Chemical Asia Pte Ltd, The Polyolefin Company (Singapore) Pte. Ltd., and Sumitomo Chemical India Limited receive legal audits from accounting auditors other than the Accounting Auditor of the Company.

(3) Description of non-audit services

The Company entrusts advisory services concerning the International Financial Reporting Standards, which are services other than the services set forth in Article 2, Paragraph 1, of the Certified Public Accountants Act (non-audit services).

(4) Policy regarding determination of termination or nonrenewal of appointment of Accounting Auditors

Aside from the termination of the Accounting Auditor pursuant to Article 340 of the Companies Act, the Board of Corporate Auditors of the Company has a policy of making a proposal to a General Meeting of Shareholders regarding the termination or nonrenewal of appointment of Accounting Auditors, following procedures pursuant to Article 344 of the Companies Act if it is determined that there is significant doubt as to whether the Accounting Auditor can continue with its duties in light of its independence and the status the execution of its duties, etc.

6. Policy for Decisions on the Distribution of Surplus

In decision on the distribution of surplus, the Company views shareholder return as one of the most important management issues, and in comprehensive consideration of factors such as business results for each term, the dividend payout ratio, and standards for internal reserves required for future business expansion, the Company's basic policy is to continue providing stable dividends. Furthermore, over the mid- to long-term, the Company aims to achieve a stable dividend payout ratio of approximately 30%.

The Company plans to utilize internal reserves for capital investment and other loans and investments with the intent of improving competitiveness in significant businesses and enriching overseas business, utilizing these in an effort to improve profitability.

Dividends are generally provided twice per year at the interim and year-end, and to flexibly implement dividends such as profit distribution to shareholders, the Company's Articles of Incorporation state that the body to determine dividends, etc., shall be the Board of Directors.

Consolidated Financial Statements

Consolidated Statement of Financial Position

			(Millions of Yen)		
Assets	139th term (As of March 31, 2020)	(Reference) 138th term (As of March 31, 2019)	Liabilities	139th term (As of March 31, 2020)	(Reference) 138th term (As of March 31, 2019)
Current assets:	1,310,906	1,291,223	Current liabilities:	1,162,328	1,005,134
Cash and cash equivalents	180,648	201,678	Bonds and borrowings	466,527	256,565
Trade and other receivables	570,413	549,992	Trade and other payables	436,070	482,858
Other financial assets	8,945	5,352	Other financial liabilities	48,769	50,735
Inventories	492,391	489,266	Income taxes payable	32,116	29,715
Other current assets	54,204	44,935	Provisions	89,862	101,340
Subtotal	1,306,601	1,291,223	Other current liabilities	88,984	83,921
Assets held for sale	4,305	–	Non-current Liabilities:	1,099,167	814,598
Non-current assets:	2,339,426	1,880,395	Bonds and borrowings	838,139	582,965
Property, plant and equipment	778,417	735,918	Other financial liabilities	92,056	87,616
Goodwill	195,998	126,838	Retirement benefit liabilities	45,770	43,981
Intangible assets	466,408	216,664	Provisions	21,491	22,698
Investments accounted for using equity method	264,054	299,044	Deferred tax liabilities	79,528	51,171
Other financial assets	488,645	323,392	Other non-current liabilities	22,183	26,167
Retirement benefit asset	61,229	69,392	Total liabilities	2,261,495	1,819,732
Deferred tax assets	47,092	70,587	Equity		
Other non-current assets	37,583	38,560	Equity attributable to owners of the parent:	922,342	998,702
			Share capital	89,699	89,699
			Capital surplus	19,135	20,438
			Retained earnings	807,959	820,454
			Treasury shares	(8,329)	(8,322)
			Other components of equity	13,878	76,433
			Non-controlling interests	466,495	353,184
Total assets	3,650,332	3,171,618	Total equity	1,388,837	1,351,886
			Total liabilities and equity	3,650,332	3,171,618

Consolidated Statement of Profit or Loss

		(Millions of Yen)
	139th term (April 1, 2019 to March 31, 2020)	(Reference) 138th term (April 1, 2018 to March 31, 2019)
Sales revenue	2,225,804	2,318,572
Cost of sales	(1,519,047)	(1,576,299)
Gross profit	706,757	742,273
Selling, general and administrative expenses	(575,135)	(590,062)
Other operating income	11,590	11,154
Other operating expenses	(14,928)	(17,594)
Share of profit of investments accounted for using the equity method	9,233	37,201
Operating income	137,517	182,972
Finance income	13,178	16,615
Finance expenses	(20,215)	(11,217)
Income before taxes	130,480	188,370
Income tax expenses	(76,081)	(35,904)
Net income	54,399	152,466
Net income attributable to:		
Owners of the parent	30,926	117,992
Non-controlling interests	23,473	34,474
Net income	54,399	152,466

Consolidated Statement of Changes in Equity

(From April 1, 2019 to March 31, 2020)

(Millions of Yen)

	Equity attributable to owners of the parent			
	Share capital	Capital surplus	Retained earnings	Treasury shares
Balance at April 1, 2019	89,699	20,438	820,454	(8,322)
Net income			30,926	
Other comprehensive income				
Total comprehensive income	—	—	30,926	—
Purchase of treasury shares				(7)
Disposal of treasury shares		0		0
Dividends			(35,970)	
Changes due to new consolidation				
Transactions with non-controlling interests		(1,303)		
Transfer from other components of equity to retained earnings			(7,465)	
Other changes			14	
Total transactions with owners	—	(1,303)	(43,421)	(7)
Balance at March 31, 2020	89,699	19,135	807,959	(8,329)

	Equity attributable to owners of the parent					
	Other components of equity					Equity attributable to owners of the parent
	Remeasurements of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans	Cash flow hedges	Exchange differences on translation of foreign operations	Total	
Balance at April 1, 2019	98,776	—	(1,851)	(20,492)	76,433	998,702
Net income					—	30,926
Other comprehensive income	(20,740)	(9,372)	2,035	(41,929)	(70,006)	(70,006)
Total comprehensive income	(20,740)	(9,372)	2,035	(41,929)	(70,006)	(39,080)
Purchase of treasury shares					—	(7)
Disposal of treasury shares					—	0
Dividends					—	(35,970)
Changes due to new consolidation					—	—
Transactions with non-controlling interests					—	(1,303)
Transfer from other components of equity to retained earnings	(1,907)	9,372			7,465	—
Other changes	(14)				(14)	—
Total transactions with owners	(1,921)	9,372	—	—	7,451	(37,280)
Balance at March 31, 2020	76,115	—	184	(62,421)	13,878	922,342

	Non-controlling interests	Total equity
Balance at April 1, 2019	353,184	1,351,886
Net income	23,473	54,399
Other comprehensive income	(1,753)	(71,759)
Total comprehensive income	21,720	(17,360)
Purchase of treasury shares		(7)
Disposal of treasury shares		0
Dividends	(16,722)	(52,692)
Changes due to new consolidation	109,256	109,256
Transactions with non-controlling interests	(943)	(2,246)
Transfer from other components of equity to retained earnings		—
Other changes		—
Total transactions with owners	91,591	54,311
Balance at March 31, 2020	466,495	1,388,837

Non-consolidated Financial Statements

<u>Non-consolidated Balance Sheet</u>			(Millions of Yen)		
Assets	139th term (As of March 31, 2020)	(Reference) 138th term (As of March 31, 2019)	Liabilities	139th term (As of March 31, 2020)	(Reference) 138th term (As of March 31, 2019)
Current assets:	482,522	458,624	Current liabilities:	420,026	555,126
Cash on hand and in banks	1,848	1,688	Trade notes payable	3,218	2,978
Trade notes receivable	1,605	773	Trade accounts payable	126,295	132,081
Trade accounts receivable	184,343	195,181	Short-term borrowing	103,784	183,147
Merchandise and finished goods	157,391	149,518	Bonds due within one year	45,000	30,000
Work in process	1,346	2,529	Commercial paper	2,000	30,000
Raw materials and supplies	43,121	41,593	Non-trade accounts payable	66,222	74,146
Non-trade accounts receivable	88,481	62,209	Accrued expenses	11,092	12,095
Other	9,536	9,330	Deposits received	37,941	65,888
Allowance for doubtful receivables	(5,148)	(4,199)	Reserve for bonuses	10,400	12,550
			Reserve for repairs	9,275	3,334
			Reserve for removal cost of property, plant and equipment	1,907	4,615
			Other	2,893	4,293
Non-current assets:	1,094,629	1,037,817	Non-current Liabilities:	841,647	591,014
Property, plant and equipment:	271,892	269,992	Bonds	445,000	205,000
Buildings	45,761	44,386	Long-term borrowing due after one year	351,146	330,649
Structures	29,203	28,991	Deferred tax liabilities	16,614	21,502
Machinery and equipment	124,841	127,096	Long-term deposits received	7,376	8,254
Vehicles	426	173	Long-term advances received	13,679	15,442
Tools and furniture	8,961	8,859	Reserve for removal cost of property, plant and equipment	2,618	3,609
Land	47,777	47,774	Reserve for repairs	2,202	3,624
Leased assets	19	27	Reserve for environmental measures	1,697	1,814
Construction in progress	14,903	12,686	Reserve for loss on business of subsidiaries and affiliates	647	562
			Other	667	558
Intangible assets:	20,877	18,363	Total liabilities	1,261,673	1,146,139
Patent	396	570	Net assets		
Software	11,703	7,799	Shareholders' equity:	288,766	301,959
Goodwill	2,141	2,796	Common stock	89,699	89,699
Other	6,637	7,199	Capital surplus:	23,698	23,698
			Additional paid-in capital	23,695	23,695
Investments and other non-current assets:	801,860	749,461	Other capital surplus	2	2
Investment securities	108,491	108,382	Retained earnings:	183,698	196,884
Investments in subsidiaries and affiliates	417,396	428,949	Legal reserve	21,361	21,361
Investments in capital	567	535	Other retained earnings	162,337	175,524
Investments in subsidiaries and affiliates' capital	109,191	52,582	General reserve	130,000	100,000
Long-term loans receivable	66,461	67,794	Retained earnings brought forward	32,337	75,524
			Treasury stock	(8,329)	(8,322)
Long-term prepaid expenses	15,933	16,981	Valuation and translation adjustments:	26,711	48,342
Prepaid pension expense	60,976	54,663	Valuation difference on available-for-sale securities	25,346	47,596
Other	23,455	20,623	Deferred gains on hedges	1,366	747
Allowance for doubtful receivables	(611)	(1,047)	Total net assets	315,477	350,301
			Total liabilities and net assets	1,577,151	1,496,440
Total assets	1,577,151	1,496,440			

Non-consolidated Statement of Income

		(Millions of Yen)
	139th term (April 1, 2019 to March 31, 2020)	(Reference) 138th term (April 1, 2018 to March 31, 2019)
Net sales	678,436	723,619
Cost of sales	556,357	576,043
Gross profit	122,079	147,576
Selling, general and administrative expenses	134,106	136,852
Operating income (loss)	(12,027)	10,724
Non-operating income	60,958	75,148
Interest and dividend income	54,545	68,843
Foreign exchange gain	–	785
Other income	6,414	5,520
Non-operating expenses	20,062	12,196
Interest expense	7,793	7,840
Foreign exchange losses	3,342	–
Bond issuance costs	2,426	–
Cost of inactive facilities	1,716	1,325
Other expenses	4,786	3,031
Ordinary income	28,869	73,676
Special gains	3,717	–
Gain on sale of investment securities	3,717	–
Special losses	5,725	6,460
Loss on disposal of property, plant and equipment	3,351	2,904
Impairment loss	1,624	546
Loss on related business	750	1,547
Loss on disaster	–	1,463
Income before income taxes	26,860	67,216
Income taxes – current	(281)	2,642
Income taxes – deferred	4,357	(2,391)
Net income	22,784	66,965

Non-consolidated Statement of Changes in Net Assets

(From April 1, 2019 to March 31, 2020)

(Millions of Yen)

	Shareholders' equity								
	Common stock	Capital surplus			Retained earnings			Treasury stock	Total shareholders' equity
		Additional paid-in capital	Other capital surplus	Total capital surplus	Legal reserve	Other retained earnings (*)	Total retained earnings		
Balance at the beginning of current period	89,699	23,695	2	23,698	21,361	175,524	196,884	(8,322)	301,959
Changes:									
Cash dividends						(35,970)	(35,970)		(35,970)
Net income						22,784	22,784		22,784
Purchase of treasury stock								(7)	(7)
Disposal of treasury stock			0	0				0	0
Net changes except for shareholders' equity									
Net changes	–	–	0	0	–	(13,187)	(13,187)	(6)	(13,193)
Balance at the end of current period	89,699	23,695	2	23,698	21,361	162,337	183,698	(8,329)	288,766

	Valuation and translation adjustments			Total net assets
	Valuation difference on available-for-sale securities	Deferred gains on hedges	Total valuation and translation adjustments	
Balance at the beginning of current period	47,596	747	48,342	350,301
Changes:				
Cash dividends				(35,970)
Net income				22,784
Purchase of treasury stock				(7)
Disposal of treasury stock				0
Net changes except for shareholders' equity	(22,250)	619	(21,631)	(21,631)
Net changes	(22,250)	619	(21,631)	(34,824)
Balance at the end of current period	25,346	1,366	26,711	315,477

* details of other retained earnings

(Millions of Yen)

	General reserve	Retained earnings brought forward	Total
Balance at the beginning of current period	100,000	75,524	175,524
Changes:			
Cash dividends		(35,970)	(35,970)
Net income		22,784	22,784
Provision of general reserve	30,000	(30,000)	–
Net changes	30,000	(43,187)	(13,187)
Balance at the end of current period	130,000	32,337	162,337

NOTES:

1. Business report is listed as follows:
 - (1) Fractions less than 0.1 billion yen or 1 million yen have been rounded to the nearest 0.1 billion yen or million yen.
 - (2) Stock prices listed in units of 1,000 are shown rounded down to the nearest 1,000 shares.
2. Fractions less than 1 million yen have been rounded to the nearest million yen with respect to the Consolidated Financial Statements, the Consolidated Statement of Profit or Loss, the Consolidated Statement of Changes in Equity, the Non-consolidated Financial Statements, the Non-consolidated Statement of Income and the Non-consolidated Statement of Changes in Net Assets.